AR122613A1 - Compuestos de metil 2-metil-5-oxo-1,4,5,7-tetrahidrofuro[3,4-b]piridina-3-carboxilato como activadores de cav1.2 - Google Patents
Compuestos de metil 2-metil-5-oxo-1,4,5,7-tetrahidrofuro[3,4-b]piridina-3-carboxilato como activadores de cav1.2Info
- Publication number
- AR122613A1 AR122613A1 ARP210101611A ARP210101611A AR122613A1 AR 122613 A1 AR122613 A1 AR 122613A1 AR P210101611 A ARP210101611 A AR P210101611A AR P210101611 A ARP210101611 A AR P210101611A AR 122613 A1 AR122613 A1 AR 122613A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- syndrome
- activators
- disorder
- tetrahydrofuro
- Prior art date
Links
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 title abstract 2
- 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title abstract 2
- YOMOFRLAYMFQFK-UHFFFAOYSA-N methyl 2-methyl-5-oxo-4,7-dihydro-1h-furo[3,4-b]pyridine-3-carboxylate Chemical class C1C(C(=O)OC)=C(C)NC2=C1C(=O)OC2 YOMOFRLAYMFQFK-UHFFFAOYSA-N 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010059027 Brugada syndrome Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000002336 repolarization Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente divulgación proporciona un compuesto de acuerdo con la fórmula (1) o una de sus sales farmacéuticamente aceptables como activadores de Caᵛ1.2 para el tratamiento de esquizofrenia, trastorno bipolar, trastorno depresivo mayor, trastorno de uso de sustancias, ADHD, síndrome de Phelan McDermid, trastorno del espectro autista, esclerosis múltiple, demencia frontotemporal, enfermedad de Alzheimer, síndrome de Brugada, síndrome de intervalo QT corto y síndrome de repolarización precoz. Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), o una de sus sales farmacéuticamente aceptables, en donde: R¹ es H o halo; y R² es etilo, isopropilo, isopropenilo, ciclopropilo, o ciclobutilo, cada uno de los cuales está opcionalmente sustituido con uno a tres halo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063039691P | 2020-06-16 | 2020-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122613A1 true AR122613A1 (es) | 2022-09-21 |
Family
ID=76523253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101611A AR122613A1 (es) | 2020-06-16 | 2021-06-11 | Compuestos de metil 2-metil-5-oxo-1,4,5,7-tetrahidrofuro[3,4-b]piridina-3-carboxilato como activadores de cav1.2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11453679B2 (es) |
| EP (1) | EP4165048B1 (es) |
| JP (1) | JP7653458B2 (es) |
| KR (1) | KR20230022979A (es) |
| CN (1) | CN115698017B (es) |
| AR (1) | AR122613A1 (es) |
| AU (1) | AU2021291799A1 (es) |
| CA (1) | CA3184192A1 (es) |
| ES (1) | ES3008091T3 (es) |
| IL (1) | IL298112A (es) |
| TW (1) | TW202214652A (es) |
| UY (1) | UY39267A (es) |
| WO (1) | WO2021255608A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021253180A1 (en) * | 2020-06-15 | 2021-12-23 | Novartis Ag | Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201395A (en) | 1981-07-30 | 1987-02-20 | Bayer Ag | Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines |
| ZA839187B (en) * | 1982-12-10 | 1984-07-25 | Ciba Geigy Ag | Amide compounds |
| EP0111455A3 (de) | 1982-12-10 | 1984-07-25 | Ciba-Geigy Ag | Ungesättigte Lactone |
| DE3410645A1 (de) | 1984-03-23 | 1985-09-26 | Bayer Ag, 5090 Leverkusen | L-alkylsubstituierte 1,4-dihydropyridinlactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| US4567268A (en) * | 1984-04-03 | 1986-01-28 | Merck & Co., Inc. | Process for preparation of certain tetrahydrofuro[3,4-b]pyridines |
| DE4430092A1 (de) * | 1994-08-25 | 1996-02-29 | Bayer Ag | 2,3-Cyclisch kondensierte 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4430639A1 (de) * | 1994-08-29 | 1996-03-07 | Bayer Ag | Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| WO2010015037A1 (en) | 2008-08-08 | 2010-02-11 | Howard Florey Institute | Therapeutic methods and compositions |
| WO2021253180A1 (en) | 2020-06-15 | 2021-12-23 | Novartis Ag | Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators |
-
2021
- 2021-06-11 CA CA3184192A patent/CA3184192A1/en active Pending
- 2021-06-11 ES ES21733558T patent/ES3008091T3/es active Active
- 2021-06-11 KR KR1020237000854A patent/KR20230022979A/ko not_active Ceased
- 2021-06-11 US US17/345,902 patent/US11453679B2/en active Active
- 2021-06-11 CN CN202180040532.6A patent/CN115698017B/zh active Active
- 2021-06-11 JP JP2022576373A patent/JP7653458B2/ja active Active
- 2021-06-11 WO PCT/IB2021/055184 patent/WO2021255608A1/en not_active Ceased
- 2021-06-11 TW TW110121337A patent/TW202214652A/zh unknown
- 2021-06-11 EP EP21733558.7A patent/EP4165048B1/en active Active
- 2021-06-11 IL IL298112A patent/IL298112A/en unknown
- 2021-06-11 UY UY0001039267A patent/UY39267A/es unknown
- 2021-06-11 AU AU2021291799A patent/AU2021291799A1/en not_active Abandoned
- 2021-06-11 AR ARP210101611A patent/AR122613A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210387995A1 (en) | 2021-12-16 |
| EP4165048B1 (en) | 2024-09-18 |
| US11453679B2 (en) | 2022-09-27 |
| JP2023531399A (ja) | 2023-07-24 |
| ES3008091T3 (en) | 2025-03-21 |
| CA3184192A1 (en) | 2021-12-23 |
| AU2021291799A1 (en) | 2023-01-19 |
| CN115698017A (zh) | 2023-02-03 |
| KR20230022979A (ko) | 2023-02-16 |
| WO2021255608A1 (en) | 2021-12-23 |
| TW202214652A (zh) | 2022-04-16 |
| IL298112A (en) | 2023-01-01 |
| UY39267A (es) | 2022-01-31 |
| JP7653458B2 (ja) | 2025-03-28 |
| CN115698017B (zh) | 2024-09-24 |
| EP4165048A1 (en) | 2023-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230008A (es) | Metil (r)-2-(fluorometil)-5-oxo-4-fenil-4,5,6,7-tetrahidro-1h-ciclopenta[b]piridin-3-carboxilato y metil (r)-2-(fluorometil)-5-oxo-4-fenil-1,4,5,7-tetrahidrofuro[3,4-b]piridin-3-carboxilato como activadores de cav1.2 | |
| CL2022001710A1 (es) | Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t | |
| AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
| DOP2019000083A (es) | COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING | |
| PE20170267A1 (es) | Compuestos heterociclicos y su uso como inhibidores gama-t del receptor huerfano relacionado con retinoide (ror) | |
| UY38767A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| AR087791A1 (es) | Derivados de benzofurano con sustitucion heterociclica y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR083358A1 (es) | Compuestos de furo[3,2-d]pirimidina | |
| AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
| HRP20200354T1 (hr) | 1,3-benzodioksol derivati kao ezh1 i/ili ezh2 inhibitori | |
| AR064010A1 (es) | Inhibidores de la actividad de la akt | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR101280A1 (es) | Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial | |
| AR090587A1 (es) | Compuestos triciclicos sustituidos con actividad hacia los receptores ep1 | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR113784A1 (es) | Compuestos de imidazopiridina y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR122613A1 (es) | Compuestos de metil 2-metil-5-oxo-1,4,5,7-tetrahidrofuro[3,4-b]piridina-3-carboxilato como activadores de cav1.2 | |
| AR109991A1 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas | |
| PE20211776A1 (es) | Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR114419A1 (es) | Compuestos y derivados de sulfonimidoilpurinona 7-sustituidos para el tratamiento y prevención del cáncer de hígado | |
| AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina | |
| AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |